This first performed randomized, placebo-controlled trial in patients with ANOCA showed that 6 weeks of therapy with diltiazem, when compared with placebo, did not substantially improve CVDys, symptoms, or quality of life, but diltiazem therapy did reduce prevalence of epicardial spasm.
EditorsEditor-in-ChiefY.S. Chandrashekhar, MD, DM, FACCCME EditorRagavendra R. Baliga, MDAuthorGbemiga G. Sofowora, MBChB, FACCImportant DatesDate of Release: August 1, 2022Term of Approval/Date of CME/MOC/ECME Expiration: July 31, 2023